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Purpose: Is to test the hypothesis that 70% xenon has a relevant
opioid sparing effect compared to a minimum alveolar concentra-
tion (MAC)-equivalent combination of N2O and desflurane.
Methods: In this randomized, controlled study of 30 patients
undergoing major orthopedic surgery, we determined the plasma
alfentanil concentration required to suppress response to skin inci-
sion in 50% of patients (Cp50) anesthetized with xenon (70%) or a
combination of N2O (70%) and desflurane (2%). A response was
defined as movement, pressor response > 15 mmHg, heart rate
> 90 beats·min–1, autonomic reactions or a combination of these.
At skin incision, alfentanil was administered at a randomly selected
target plasma concentration thereafter the concentration was
increased or decreased according to the patient’s response. After
skin incision, desflurane was adjusted to maintain the bispectral
index below 60 and prevent responsiveness in both groups.
Results: The Cp50 (± standard error) of alfentanil was 83 ± 48
ng·mL–1 with xenon and 49 ± 26 ng·mL–1 with N2O/desflurane (P
= 0.451). During surgery five xenon and 15 N2O/desflurane
patients were given desflurane at 1.0 ± 0.5 volume % and 2.5 ±
0.7 volume %. The total age adjusted MAC was 0.97 ± 0.07 and
0.94 ± 0.07 respectively (P = 0.217). The intraoperative plasma
alfentanil concentrations were 95 ± 80 and 93 ± 60 ng·mL–1
respectively (mean ± SD; P = 0.451). Patients given xenon were
slightly more bradycardic, whereas blood pressure was similar.
Conclusion: Xenon compared to a MAC-equivalent combination
of N2O and desflurane does not substantially reduce opioid
requirement for orthopedic surgery. A small but clinically irrelevant
difference cannot be excluded, however.
Objectif : Vérifier l’hypothèse voulant que le xénon à 70 % permette
de réduire significativement les opioïdes en comparaison d’une combi-
naison équivalente de concentration alvéolaire minimale (CAM) de
N2O et de desflurane.
Méthode : L’étude randomisée et contrôlée comptait 30 patients
devant subir une intervention orthopédique majeure. La concentration
plasmatique d’alfentanil nécessaire pour supprimer la réaction à une
incision cutanée chez 50 % des patients (Cp50) sous anesthésie au
xénon (70 %) ou une combinaison de N2O (70 %) et de desflurane
(2 %) a été déterminée. Une réaction était un mouvement, une
réponse vasopressive > 15 mmHg, une fréquence cardiaque > 90
battements·min–1, des réactions autonomes ou une des réactions
combinées. Lors de l’incision cutanée, l’alfentanil était administré selon
une concentration plasmatique cible choisie aléatoirement, et la con-
centration augmentée ou diminuée selon la réaction du patient. Après
l’incision, le desflurane était ajusté pour maintenir l’index bispectral en
bas de 60 et éliminer les réactions chez tous les patients.
Résultats : La Cp50 (± erreur type) de l’alfentanil a été de 83 ±
48 ng·mL–1 avec le xénon et de 49 ± 26 ng·mL–1 avec N2O/desflu-
rane (P = 0,451). Pendant l’opération, cinq patients sous xénon et 15
sous N2O/desflurane ont reçu du desflurane à 1,0 ± 0,5 volume % et
2,5 ± 0,7 volume %. L’ajustement total de la CAM en fonction de
l’âge a été de 0,97 ± 0,07 et de 0,94 ± 0,07 respectivement (P =
0,217). les concentrations plasmatiques d’alfentanil ont été de 95 ±
80 et de 93 ± 60 ng·mL–1 respectivement (moyenne ± écart type ;
P = 0,451). Les patients qui ont reçu du xénon ont présenté un peu
plus de bradycardie, mais la tension artérielle était similaire entre les
groupes.
Conclusion : Le xénon, comparé à une CAM d’une combinaison
équivalente de N2O et de desflurane, ne réduit pas significativement
les besoins d’opioïdes en orthopédie. On ne peut toutefois exclure une
petite différence, mais cliniquement non significative.
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ORE than ten years ago Lachmann and
co-workers detected a fivefold reduc-
tion of the fentanyl requirement for
general surgery in patients anes-
thetized with 70% xenon compared to those anes-
thetized with 70% nitrous oxide (N2O) in oxygen.
1
These results triggered a number of subsequent stud-
ies documenting the fast induction and emergence
kinetics2 and the cardiovascular stability of xenon.3,4
Xenon was also suggested as a potential alternative to
N2O because it is not teratogenic.
5 A recent random-
ized, controlled, multicentre study showed that anes-
thesia with xenon is safe and provides a more rapid
recovery than isoflurane with N2O.
6
Although it is not surprising that the patients in the
study by Lachmann and co-workers1 receiving one min-
imum alveolar concentration (MAC) of xenon required
less fentanyl than the patients receiving 0.7 MAC of
N2O, the difference was far greater than expected from
the difference in MAC. Because of its weak hypnotic
effect N2O (with a MAC-awake of 63%)
7 must be sup-
plemented by a potent volatile or iv anesthetics to pre-
vent awareness.8 The insufficient hypnosis of the N2O
patients might, therefore, have biased Lachmann’s
study. We defined a control group where a sufficient
depth of hypnosis would be ascertained by adding small
concentrations of desflurane to N2O. Adding 2.8 vol-
ume % of desflurane to 60% N2O corresponds to 1
MAC in middle-aged subjects.9 Assuming the two
agents are additive, we considered 70% N2O plus 2 vol-
ume % desflurane as MAC-equivalent to 70% xenon.10
Because the MAC-awake of xenon is 33%,7 we consid-
ered 70% xenon sufficiently hypnotic.
Given the large opioid sparing effect of xenon
reported by Lachmann and co-workers1 we hypothe-
sized that opioid requirements would be lower in xenon
anesthetized patients even if control patients were given
a MAC-equivalent combination of N2O/desflurane.
We determined the alfentanil plasma concentration
required to suppress the response to skin incision in
50% of patients (Cp50) and the median alfentanil con-
centration necessary to suppress response to intraoper-
ative surgical stimulation in patients anesthetized with
70% xenon or N2O supplemented with desflurane to
maintain the bispectral index (BIS) level below 60 and
to prevent responsiveness.
Methods
With approval of the local Ethical Committee and
written informed consent, we recruited 30 ASA phys-
ical status I and II patients scheduled for elective
orthopedic surgery. Patients were stratified11 accord-
ing to age and type of surgery and randomly assigned
to either xenon or N2O plus desflurane (N2O/desflu-
rane) anesthesia. Patients with diabetes mellitus; any
relevant renal, liver, heart (including arterial hyperten-
sion), neurological, or psychiatric disease; a regular
alcohol consumption of more than 20 g per day,12
drug abuse; or taking sedatives or long acting anal-
gesic drugs were excluded. Additional details on the
methods are available as Additional Material at
www.cja-jca.org.
Study plan
Thirty minutes after premedication with 7.5 mg mida-
zolam po the patients were monitored with a Datex
AS3 monitor and an Aspect A1000 BIS monitor (BIS
version 3.2, Aspect Medical Systems, Inc., Newton,
MA, USA). Anesthesia was induced with 2.5 mg·kg–1
propofol, 1 µg·kg–1 remifentanil, and 0.1 mg·kg–1
vecuronium to facilitate tracheal intubation. After
induction, desflurane was administered at 3 volume %
and an arterial catheter was inserted into the radial
artery of the non-dominant arm. A computer-con-
trolled infusion of alfentanil was started at a randomly
selected alfentanil target plasma concentration
between 5 and 400 ng·mL–1 (Stanpump program,
pharmacokinetic parameters for alfentanil by Raemer
et al.13 software freely available from S.L. Shafer,
M.D., Palo Alto, CA, USA). The study gas (either
70% N2O or xenon) was then started (at least 15 min
before Cp50) and desflurane was eliminated by use of
a charcoal filter in the xenon group whereas it was
reduced to 2 volume % in the N2O group. The maxi-
mal systolic blood pressure, heart rate, and any motor
reaction within five minutes of skin incision were
recorded. During surgery the xenon and N2O con-
centrations were kept constant at 70 volume % where-
as the target plasma alfentanil concentration was
increased by 25 to 50 ng·mL–1 if the patient showed
any response to incision as defined below. Conversely
alfentanil was decreased by 25 ng·mL–1 if the patient
did not show any response to the surgical stimulation
during the last 20 min. The maximal target alfentanil
concentration allowed was 500 ng·mL–1. The patient’s
responsiveness to verbal command was checked every
20 min (isolated forearm technique). To prevent
awareness and recall desflurane was adjusted in steps
of 0.5 volume % in order to maintain the BIS below
60 and to prevent responsiveness. Desflurane was
therefore allowed also in the xenon group as a rescue
drug, if the patient was responsive or if the BIS
increased above 60 for longer than four minutes.14
A response to skin incision or to intraoperative sur-
gical stimulation was defined as a motor response, a
blood pressure increase of more than 15 mmHg above
M
baseline, a heart rate increase above 90 beats·min–1 in
the absence of hypovolemia, an autonomic response
(such as tearing, sweating, or flushing) or a combina-
tion of these.15 Baseline systolic blood pressure was
defined as the average of measurements taken on the
ward the day before surgery and in the operating
room before induction.
All the data from the Datex AS3 monitor, the
Aspect A1000 and a Dräger thermal conductivity sen-
sor measuring the xenon concentration16 were record-
ed on a computer disk.
At baseline, immediately before and at five minutes
after skin incision, and before and two to five minutes
after each change of the target alfentanil concentration
during surgery, an arterial blood sample was with-
drawn for determination of the alfentanil plasma con-
centration. Blood samples for alfentanil measurement
were immediately centrifuged at 3500 g for 30 min
and the plasma stored at -26°C. Alfentanil plasma con-
centration was measured by gas chromatography mass
spectrometry.17
On the second day after surgery a blinded investi-
gator interviewed the patients for signs of explicit
recall.
Data analysis and statistics
The alfentanil concentration to suppress patient
response to skin incision was computed by logistic
regression for the two study groups using NONMEM
software (Sheiner LB, Beal SL: NONMEM user’s
Guide 1994, University of California San Francisco,
CA, USA). For the intraoperative period the median
of the plasma alfentanil concentrations measured
between skin incision and closure and the median
alfentanil infusion rate was determined.
According to Ausems et al.15 the CP50 ± standard
error (SE) of alfentanil to suppress response to Cp50 is
279 (20) ng·mL–1 (n = 37) in a mixed population and
to suppress an intraoperative response in breast surgery
270 ± 63 ng·mL–1 in patients anesthetized with N2O in
oxygen without potent volatile anesthetics. With 15
subjects per group, we expected to detect a difference
of 50 ng·mL–1 between groups with a power of > 0.80
(one tailed t test).
The number of blood pressure recordings greater
than 20% or below 20% of baseline, the number of
heart rate recordings above 90 min–1 or below 20% of
baseline and the number of episodes with BIS > 60 for
longer than four minutes were determined for each
subject.18
Data were compared with a Student’s t test or a
Wilcoxon rank test as appropriate. Results are present-
ed as means ± SDs or number of patients, unless oth-
erwise noted. P < 0.05 was considered significant.
Results
The characteristics of the two study groups were sim-
ilar (Table I).
Response to skin incision
Two patients in each group were excluded from the
analysis because the desflurane concentration acciden-
tally differed more than 20% from the target value.
The train-of-four count at Cp50 was four twitches in
every subject. The Cp50 for alfentanil was 83 ± 48
ng·mL–1 in the xenon group and 48 ± 25 ng·mL–1 in
the N2O/desflurane group (parameter estimate ± SE,
P = 0.451; Figure 1).
Response during surgery
All 15 patients of each group were included in the
analysis. The median plasma alfentanil concentration
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TABLE I Characteristics of the study population
Xenon N2O/desflurane P value
Men/women 7/8 9/6 0.49
Age; yr 32 ± 6 33 ± 11 0.60
Weight; kg 69 ± 14 72 ± 16 0.53
Height; cm 172 ± 6 172 ± 12 0.62
BMI* 23 ± 4 24 ± 4 0.35
ASA status (I/II) 14/1 12/3 0.59
Baseline systolic pressure; mmHg 124 ± 13 121 ± 11 0.54
Type of surgery
Hip dislocation 11 9 0.70
Periacetabular osteotomy 3 4 1.0
Low back surgery 1 2 1.0
Duration of surgery; min 151 ± 60 136 ± 28 0.42
Data presented as mean ± SD or number of patients. N2O = nitrous oxide; *BMI = body mass index.
during surgery and the median alfentanil infusion rate
to prevent intraoperative response was similar in the
two groups (Table II). Five of 15 patients were given
desflurane (1.0 ± 0.4 volume %) in addition to xenon
because of a sustained BIS increase > 60 (four sub-
jects) and uncontrollable blood pressure increase
despite 500 ng·mL–1 of alfentanil (one subject). In
these patients the mean (SD) BIS level was 46 (8) and
the median alfentanil concentration was 111 (127)
ng·mL–1. In xenon patients without desflurane the
mean (SD) BIS level was 36 (8) and the median alfen-
tanil concentration was 86 (49) ng·mL–1 (P = 0.075
for BIS, P = 0.58 for alfentanil). In the patients under-
going hip arthrotomy with surgical dislocation of the
hip19 the median alfentanil concentration during
surgery was 100 (39) ng·mL–1 in the N2O/desflurane
and 96 (92) ng·mL–1 in the xenon group (P = 0.92).
Excluding the three xenon patients of this subgroup
who were given desflurane, the median alfentanil con-
centration during surgery was 82 (54) ng·mL–1 (P =
0.43 compared to the N2O/desflurane patients).
No patient responded to verbal command during
surgery. One patient in the N2O/desflurane group
experienced awareness with recall during tracheal
intubation because of a failure of desflurane supply
before administration of the study gas.20
Discussion
In a previous study xenon, compared to N2O, was
associated with a reduction of fentanyl requirement by
far exceeding the difference in MAC of the two gases.1
In contrast, our data do not show a relevant reduction
of alfentanil requirements to suppress hemodynamic,
autonomic or motor responses to Cp50 in xenon
patients compared to those receiving a MAC-equiva-
lent combination of N2O and desflurane. There was
no difference in the alfentanil infusion rate and the
mean measured alfentanil concentration during
surgery even though the BIS level was lower in the
xenon patients. The anesthetic regimens provided
similar hemodynamic stability except for a higher inci-
dence of bradycardia in the xenon group and a lower
arterial pressure in the N2O/desflurane group. Xenon
as the main anesthetic does not have an opioid sparing
effect compared to a MAC-equivalent combination of
N2O and desflurane.
Suppression of motor response to skin incision
(MAC) has been the gold standard to measure the
potency of anesthetics. It reflects mainly a spinal reflex
independent of the anesthetic drug concentration in
the brain, however.21 This is illustrated by the fact that
the BIS did not predict movement response to inser-
tion of a laryngeal mask.22 It is therefore not surpris-
ing that the BIS levels in the two study groups were
different even though the post hoc calculation of age-
adjusted total MAC was similar. If xenon had a true
opioid-sparing effect, the alfentanil concentrations to
suppress response to painful surgical stimulation
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FIGURE 1 The predicted probability of no-response to skin
incision (Cp50) is plotted in relation to the measured plasma alfen-
tanil concentration. Responders and non-responders of the xenon
group are represented by filled circles and those of the nitrous
oxide (N2O)-desflurane group by open circles. The filled and open
squares represent the Cp50 of alfentanil in the xenon and the
N2O/desflurane group respectively (error bars = standard error of
the estimate).
FIGURE 2 The measured plasma alfentanil concentrations
between skin incision and closure are plotted for each subject.
Solid lines with filled circles = xenon patients, dashed lines with
triangles = nitrous oxide (N2O)/desflurane patients.
would have been smaller even at a MAC-equivalent
concentration. The difference in BIS level can be
explained by the weak sedative effect of N2O, which
does not affect BIS.23 The BIS is a validated tool to
measure depth of sedation with various iv and inhala-
tion anesthetics; among them N2O plus desflurane
24
but not xenon. The BIS did not predict responsiveness
to verbal command at emergence of xenon anesthe-
sia.25 The deeper BIS levels in the xenon patients are
therefore difficult to interpret and may not necessarily
indicate a deeper hypnosis. Whatever the lower BIS
levels mean, hemodynamic response and alfentanil
requirements were not affected. Because of this uncer-
tainty, desflurane was administered in four xenon
patients because of a persistent BIS increase. Also, in
these patients, alfentanil requirements were similar to
those not given desflurane.
A xenon MAC of 71%26 was the basis for the poten-
cy calculations for our study; however, in a recent
study a MAC of 63% was reported for xenon.27 The
70% xenon we used did not only produce significant-
ly lower BIS levels, but might even have been more
potent than the combination of 70% N2O and 2% des-
flurane. Although this would suggest that the xenon
patients would require less alfentanil they did not.
Assuming a potency ratio of 1:70 between alfentanil
and fentanyl,28 the plasma alfentanil concentration to
prevent response to skin incision in our study (83
ng·mL–1 in the xenon and 49 ng·mL–1 in the
N2O/desflurane group) was in the same range as the
value reported for fentanyl (0.94 ng·mL–1).29
The limitation of our primary sample size calcula-
tion was that it had to be based on data from a study
with a somewhat different design (e.g., N2O without
volatile anesthetics). Compared to previous studies on
alfentanil requirements to suppress motor and hemo-
dynamic response to Cp50 or intraoperative surgical
stimuli15,30 we observed substantially greater standard
deviations of our Cp50 values. A post hoc power analy-
sis revealed that 15 subjects per group would allow
detecting a difference between groups greater than
125 ng·mL–1 for Cp50 and greater than 80 ng·mL
–1 for
intraoperative alfentanil requirements with a power
greater than 0.8. Our Cp50 of alfentanil were below
100 ng·mL–1 in both groups and thus far below the
Cp50 for naloxone requirement of 223 (13) ng·mL
–1
reported by Ausems et al.15 In order to reach sufficient
power to detect a difference of 50 ng·mL–1 as many as
150 patients per group would have been necessary.
Due to the small sample size we therefore might have
missed a small opioid sparing effect of xenon but we
can exclude a substantial difference as reported by
Lachmann and co-workers.15 In view of the high cost
of this inhalation anesthetic a small difference would
not be clinically relevant, however.
Using a stratified randomization protocol, the type
of surgery was well balanced between the two groups
(Table I). In the subgroup analysis of patients under-
going surgical dislocation of the hip (11 in the xenon
and nine in the N2O/desflurane group) alfentanil
requirements were not significantly different, even
when the three xenon patients who were given desflu-
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TABLE II Hemodynamic responses, anesthetic gas concentrations and BIS level
Xenon N2O/desflurane P value
Desflurane at skin incision (vol %) 0.10 ± 0.09 1.9 ± 0.1 < 0.001
BIS reading at skin incision 34 ± 10 55 ± 11 < 0.001
Gas concentration (vol %) 70.7 ± 1.3 70.1 ± 0.6 0.101
Desflurane during surgery (vol %)* 1.0 ± 0.4 2.5 ± 0.7 0.002
MAC during surgery† 0.97 (0.06) 0.94 (0.07) 0.22
BIS reading during surgery 40 ± 10 54 ± 4 < 0.001
Median alfentanil plasma conc. (ng·mL–1)‡ 95 ± 80 93 ± 60 0.95
Median alfentanil rate (µg·kg–1·min–1)‡ 0.47 (0.30–0.63) 0.38 (0.36–0.55) 0.455
SAP; mmHg‡ 128 ± 12 114 ± 10 0.002
SAP > upper limit (%)‡§ 10.4 (3–13.5) 0.3 (0–8) 0.005
SAP < lower limit (%)‡¶ 4.6 (4.1–6.1) 4.4 (3.9–26.2) 0.772
HR; beats·min–1‡ 54 ± 6 59 ± 9 0.117
HR > upper limit (%)‡ 0 (0–0.2) 0 (0–0.5) 0.868
HR < lower limit (%)‡¶ 93 (66–99) 51 (15–92) 0.031
Data presented as mean ± SD or medians (inter-quartile range) as appropriate. *Calculated from the subjects given desflurane: five in the
xenon group, 15 in the N2O/desflurane group; †Age-adjusted total MAC (study gas + desflurane); ‡During surgery; §Systolic pressure
upper limit = 15 mmHg above baseline; ¶Lower limit = 20% lower than baseline;  Heart rate upper limit = 90 beats·min–1. BIS = bispec-
tral index; N2O = nitrous oxide; MAC = minimum alveolar concentration; SAP = systolic arterial pressure; HR = heart rate.
rane are excluded. Even highly standardized condi-
tions (one standardized operation) did not allow to
detect a clinically relevant and statistically significant
opioid sparing effect of xenon.
The definition of a response was previously used by
Ausems and co-workers15 and is closest to clinical prac-
tice, where motor response, hemodynamic response or
autonomic signs of inadequate anesthesia are also con-
sidered together for dosing anesthetic drugs.
Because of the uncertainty of the BIS as a measure
of hypnotic depth during xenon anesthesia15 we addi-
tionally used the isolated forearm technique for clini-
cal assessment of responsiveness. Since the duration of
tourniquet inflation was similar in both groups (corre-
sponding to the similar top-up doses of vecuronium),
we assume that a potential hemodynamic response to
tourniquet inflation would have been similar in both
groups. One patient from the N2O/desflurane group
reported awareness and recall in the postoperative
interviews.20 This episode was well before the first
study period and actually not related to the adminis-
tration of the study gas.
Cardiovascular stability in our healthy patients anes-
thetized with a combination of N2O and desflurane was
similar than in those anesthetized with xenon. Low
concentrations of desflurane, as applied in our study,
sufficient to maintain a BIS of 40 to 65, were adminis-
tered successfully in patients with inoperable coronary
artery disease with a mean ejection fraction of 49%.31
Despite the negative inotropic effect of desflurane, the
ability of the heart to respond to increased preload was
preserved in patients with a mean ejection fraction of
53% undergoing coronary surgery.32 Thus, the true
clinical utility of xenon justifying its cost remains open
to question. Eventually, an ongoing study in patients
with poor cardiovascular function may demonstrate
some advantage of xenon over conventional anesthetics
or its unique neuroprotective effect33,34 detected in ani-
mal studies will be more important.
We conclude that alfentanil requirements and
hemodynamic stability in healthy patients anesthetized
with xenon and a MAC-equivalent combination of
N2O and desflurane are similar.
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